BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27229618)

  • 1. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
    Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists.
    Krasavin M; Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Borysko P; Zozulya S; Moore D; Tikhonova IG
    Eur J Med Chem; 2017 Nov; 140():229-238. PubMed ID: 28938138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-2-yl)propanoic acid scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1404-10. PubMed ID: 26899762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
    Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
    Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
    Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
    Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
    Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S; Ihalainen J; Forsberg MM; Lehtonen M; Rautio J; Moore D; Tikhonova IG
    Bioorg Med Chem; 2016 Nov; 24(21):5481-5494. PubMed ID: 27647366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
    Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
    Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.
    Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q
    Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
    Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
    Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
    Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
    Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
    Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.